282 related articles for article (PubMed ID: 14603351)
41. [Rationale of antiangiogenic therapy].
Tímár J; Paku S; Tóvári J; Döme B
Magy Onkol; 2006; 50(2):141-51. PubMed ID: 16888678
[TBL] [Abstract][Full Text] [Related]
42. Angiogenesis and antiangiogenic therapy in hematologic malignancies.
Dong X; Han ZC; Yang R
Crit Rev Oncol Hematol; 2007 May; 62(2):105-18. PubMed ID: 17188504
[TBL] [Abstract][Full Text] [Related]
43. [Tumour angiogenesis and therapy directed at the neovasculature].
Eikesdal HP; Dahl O; Straume O; Akslen LA
Tidsskr Nor Laegeforen; 2004 Aug; 124(15):1919-22. PubMed ID: 15306859
[TBL] [Abstract][Full Text] [Related]
44. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y
Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
[TBL] [Abstract][Full Text] [Related]
45. Antiangiogenesis in haematological malignancies.
Li WW; Hutnik M; Gehr G
Br J Haematol; 2008 Dec; 143(5):622-31. PubMed ID: 19036013
[TBL] [Abstract][Full Text] [Related]
46. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
47. Combining angiogenesis inhibition and radiotherapy: a double-edged sword.
Kleibeuker EA; Griffioen AW; Verheul HM; Slotman BJ; Thijssen VL
Drug Resist Updat; 2012 Jun; 15(3):173-82. PubMed ID: 22561672
[TBL] [Abstract][Full Text] [Related]
48. Angiogenesis and breast cancer.
Hayes DF
Hematol Oncol Clin North Am; 1994 Feb; 8(1):51-71. PubMed ID: 7512088
[TBL] [Abstract][Full Text] [Related]
49. Angiogenic tumor markers, antiangiogenic agents and radiation therapy.
Chan LW; Camphausen K
Expert Rev Anticancer Ther; 2003 Jun; 3(3):357-66. PubMed ID: 12820778
[TBL] [Abstract][Full Text] [Related]
50. Angiogenesis and Cancer Control: From Concept to Therapeutic Trial.
Brem S
Cancer Control; 1999 Oct; 6(5):436-458. PubMed ID: 10758576
[TBL] [Abstract][Full Text] [Related]
51. Angiogenesis: What can it offer for future medicine?
Cao Y
Exp Cell Res; 2010 May; 316(8):1304-8. PubMed ID: 20206162
[TBL] [Abstract][Full Text] [Related]
52. Molecular targets on blood vessels for cancer therapies in clinical trials.
Sato M; Arap W; Pasqualini R
Oncology (Williston Park); 2007 Oct; 21(11):1346-52; discussion 1354-5, 1367, 1370 passim. PubMed ID: 18080618
[TBL] [Abstract][Full Text] [Related]
53. [Immunomodulation and antiangiogenesis in cancer therapy. From basic to clinical research].
Scharovsky OG; Matar P; Rozados VR; Rico MJ; Zacarías Fluck MF; Mainetti LE; Fernández Zenóbi MV; Roggero EA; Gervasoni SI; Rossa A; Perroud HA; Sánchez AM; Celoria GC; Font MT
Medicina (B Aires); 2012; 72(1):47-57. PubMed ID: 22257459
[TBL] [Abstract][Full Text] [Related]
54. [Angiogenesis in cancer].
Pozner RG; Negrotto S; Schattner M
Medicina (B Aires); 2002; 62(6):604-6. PubMed ID: 12532700
[No Abstract] [Full Text] [Related]
55. Therapeutic potential of inhibitory VEGF splice variants.
Bates DO; Harper SJ
Future Oncol; 2005 Aug; 1(4):467-73. PubMed ID: 16556023
[TBL] [Abstract][Full Text] [Related]
56. Antiangiogenesis and radiotherapy: what is the role of combined modality treatment?
Classen J; Budach W
Curr Med Chem Anticancer Agents; 2003 Sep; 3(5):375-82. PubMed ID: 12871084
[TBL] [Abstract][Full Text] [Related]
57. [The role of copper in tumor angiogenesis--clinical implications].
Nasulewicz A; Opolski A
Postepy Hig Med Dosw; 2002; 56(6):691-705. PubMed ID: 12661402
[TBL] [Abstract][Full Text] [Related]
58. Antiangiogenic strategies and agents in clinical trials.
Rosen L
Oncologist; 2000; 5 Suppl 1():20-7. PubMed ID: 10804087
[TBL] [Abstract][Full Text] [Related]
59. Emerging strategies in the management of cancer.
Rieger PT
Oncol Nurs Forum; 1997 May; 24(4):728-37. PubMed ID: 9159787
[TBL] [Abstract][Full Text] [Related]
60. Closing in on cancer.
Park A
Time; 2001 May; 157(20):60, 62. PubMed ID: 11383110
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
